FDA Expands Besremi to Adults With Essential Thrombocythemia
FDA approved ropeginterferon alfa-2b-njft, marketed as Besremi, for adults with essential thrombocythemia regardless of genotype or disease status. The decision creates a long-acting interferon option across the labeled adult population and represents the first…
